Examination of Questionnaire Items regarding Diabetic Peripheral Neuropathy in Epalrestat-treated Patients and Their Usefulness in the Treatment of This Disorder — Influence on Treatment Course

Atsuo ITO; Reiko ISHII-NOZAWA; Chikao IBUKI; Hirotsugu ATARASHI; Hirokuni KATAOKA; Koichi TAKEUCHI

doi:10.1248/yakushi.129.1239

Regular Articles

Examination of Questionnaire Items regarding Diabetic Peripheral Neuropathy in Epalrestat-treated Patients and Their Usefulness in the Treatment of This Disorder — Influence on Treatment Course

Atsuo ITO ^†, Reiko ISHII-NOZAWA ^†, Chikao IBUKI ^†, Hirotsugu ATARASHI ^†, Hirokuni KATAOKA ^†, Koichi TAKEUCHI ^†

Author information

Keywords: diabetes mellitus, somatic neuropathy, autonomic neuropathy, epalrestat, aldose reductase inhibitor, questionnaire

JOURNAL FREE ACCESS

2009 Volume 129 Issue 10 Pages 1239-1247

DOI https://doi.org/10.1248/yakushi.129.1239

Details

Abstract

Epalrestat (Kinedak^®) is an aldose reductase inhibitor (ARI) for diabetic peripheral neuropathy. In 41 diabetics, we conducted a questionnaire survey to evaluate symptoms of peripheral neuropathy and select appropriate drug therapy. We investigated 27 patients who participated in the first and second questionnaire surveys. We reviewed questionnaire items, and examined the correlation between the therapeutic effects and responses to the questionnaire. Concerning the usefulness of the questionnaire items, some questions were correlated with the effects. Treatment was effective for somatic neuropathy, but not for autonomic neuropathy. The questionnaire regarding diabetic peripheral neuropathy was useful for somatic neuropathy screening, but it was difficult to detect autonomic neuropathy.

Corresponding author

Register with J-STAGE for free!